Our specialist medical device team work with diverse global companies within the industry to sustain growth, exploit current and future innovations, and secure their business's success. Our clients are multinational corporations and start-ups within the medical devices industry from companies within medical devices or in vitro diagnostic medical devices.
With sector-specific expertise grounded in scientific intelligence and technological know-how, clients value our knowledge of the regulatory frameworks shaping clients' strategic options, the technology being deployed, and our ability to execute complex legal solutions across multi-jurisdictions.
We ensure that our clients operate within the boundaries of medical regulations, data privacy, competition/anti-trust, procurement, pricing and reimbursement, advertising and promotion, and anti-bribery compliance/fraud and abuse laws.
We are pivotal in leveraging growth through strategic alliances, fundraisings, IP and compliant data privacy and security activities, and are relied on to resolve both offensive and defensive cross-jurisdiction patent litigation.
With in-depth sector expertise, we also actively engage with the wider medical devices industry through our connections with esteemed industry bodies and as leading voices in industry publications and wider expert webinar/seminar series.
Die börsennotierte Eckert & Ziegler Strahlen- und Medizintechnik AG, einer der weltweit größten Anbieter von isotopentechnischen Komponenten für Strahlentherapie und Nuklearmedizin mit Sitz in Berlin, hat die ebenfalls börsennotierte belgische Eckert & Ziegler BEBIG SA übernommen. Die internationale Wirtschaftskanzlei Taylor Wessing hat die Eckert & Ziegler Strahlen- und Medizintechnik AG hinsichtlich aller Aspekte der grenzüberschreitenden Verschmelzung rechtlich beraten. Die Transaktion dürfte die erste erfolgreiche Umsetzung einer grenzüberschreitenden Verschmelzung zweier börsennotierter Gesellschaften nach Deutschland auf der Grundlage der europäisch harmonisierten Vorgaben der EU-Gesellschaftsrichtlinie (EU) 2017/1132 sein.
Press release
Aktuelle News & Insights
Updated post-market surveillance (PMS) rules for medical devices in the UK: differences from the EU regulations
von Alison Dennis und Alice Matthews
Podcast: Medizintechnik ist kein einfacher Markt
Dr. Marina Schulte über das Reimbursement
Purpose limitation and data minimisation: key considerations for AI training in the life sciences sector
The use of real-world evidence data to train AI models is becoming a critical component in advancing research and drug development. We explore how two of the GDPR's guiding principles are more than just regulatory requirements.
von Victoria Hordern und Dr. Tim Schwarz
3 von 10 Insights
The UPC: a new rocket docket for life sciences patent litigation
von Dr. Anja Lunze, LL.M. und Dr Paul England
Orphan drug protection: clarification needed
von Dr Paul England